Boehringer expands commercial manufacturing capacities in China

Germany’s Boehringer Ingelheim said today it has initiated a capacity expansion at its commercial manufacturing site for biologics in China. The expansion covers an additional bioreactor and includes all needed utility and infrastructure to support the GMP operations of 2x 2.000L single use bioreactor manufacturing lines.

“We are fully committed to our biopharmaceutical contract manufacturing business in China and it is our utmost goal to serve our customers and their patients with high quality medicines in China and in the global market,” said Prof Dr Buecheler, head of the Biopharmaceutical Business Unit at family-owned Boehringer Ingelheim.

Boehringer’s biopharmaceutical contract manufacturing business is expected to begin manufacturing the commercial supply of a monoclonal antibody (Mab) out of its China manufacturing OASIS facility in 2019. This will be the first commercial drug manufactured in the Shanghai facility, OASIS, an important part of Boehringer’s global biopharmaceutical production network. Following the commercial manufacturing of a client’s antibody, a number of investigational drugs are in Boehringer’s contract manufacturing business pipeline for potential future market launch and commercial supply out of Shanghai, China.